Download Sample
Add to CartPediatric Vaccine Market
By Vaccine Type;
Monovalent Vaccines, and Multivalent VaccinesBy Technology;
Conjugate Vaccine, Inactivated or Killed Vaccine, Live or Attenuated Vaccine, Recombinant Vector Vaccine, Subunit Vaccine, and Toxoid VaccineBy Indication;
DTP Vaccine, Influenza, Meningococcal Vaccine, MMR Vaccine, Pneumococcal Conjugate Vaccine, Polio Vaccine, Rotavirus Vaccine, and Varicella Virus VaccineBy End Use;
Hospital Pharmacies, Institutional Health Centres, and Retail PharmaciesBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).Paediatric Vaccine Market Overview
Paediatric Vaccine Market (USD Million)
Paediatric Vaccine Market was valued at USD 50,771.96 million in the year 2024. The size of this market is expected to increase to USD 99,571.53 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 10.1%.
Pediatric Vaccine Market
*Market size in USD million
CAGR 10.1 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 10.1 % |
| Market Size (2024) | USD 50,771.96 Million |
| Market Size (2031) | USD 99,571.53 Million |
| Market Concentration | Low |
| Report Pages | 381 |
Major Players
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Johnson & Johnson
- Novavax, Inc.
- AstraZeneca plc
- Bharat Biotech
- Sinovac Biotech Ltd.
- Serum Institute of India Pvt. Ltd.
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Pediatric Vaccine Market
Fragmented - Highly competitive market without dominant players
The Paediatric Vaccine Market is witnessing strong momentum, driven by increasing immunization awareness and the emergence of advanced vaccine technologies. Over 65% of healthcare providers have enhanced their paediatric vaccine initiatives due to improved accessibility and innovation. Strategic efforts toward universal immunization coverage have significantly elevated vaccine deployment across institutional channels. This expansion is also backed by supportive health agendas and collaborative efforts between public and private sectors.
Technological Innovations in Vaccine Development
Modern biotechnology platforms are reshaping the paediatric vaccine landscape, enabling the creation of highly effective and safer vaccine formulations. With over 52% of the market now driven by recombinant and conjugate technologies, manufacturers are investing in innovative delivery systems and formulation methods. These technological advancements are not only increasing efficacy but also supporting long-term immunity. The push toward next-generation vaccines is opening new avenues for product development and optimization.
Opportunities for Growth and Investment
The market is presenting multiple growth opportunities as healthcare agencies continue to prioritize preventive care and reduce disease burden through vaccination. Around 55% of healthcare investors are shifting focus toward paediatric immunization technologies, driven by increasing demand and favorable returns. This trend is creating room for new entrants and expansion by established firms. Stakeholders are leveraging this momentum by adopting scalable production strategies and digital health integration.
Future Outlook and Strategic Focus
The future outlook for the Paediatric Vaccine Market remains highly promising, with continuous emphasis on research, innovation, and policy alignment. More than 60% of industry leaders are prioritizing long-term partnerships and sustainable vaccine pipelines to meet evolving healthcare demands. Emphasis on technological advancements such as mRNA platforms and AI-based surveillance tools is expected to further enhance vaccine responsiveness. As expansion progresses, the market is poised to remain a central focus of public health strategies.
Paediatric Vaccine Market Recent Developments
-
In March 2024, the European Commission approved Pfizer's PREVENAR 20, a vaccine that provides the broadest serotype coverage to protect children against pneumococcal disease. This approval is supported by extensive Phase 3 trial data confirming its safety and efficacy and follows.
-
In November 2023, Indian Immunologicals Limited (IIL) launched a new measles and rubella vaccine for children called Mabella. Developed in collaboration with the Polyvac Institute of Vietnam, this live-attenuated vaccine has undergone rigorous clinical trials that have demonstrated its safety and effectiveness.
Segment Analysis
This report extensively covers different segments of Global Paediatric Vaccine Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).
The global paediatric vaccine market has been segmented based on vaccine type, end use, and geography, allowing for targeted approaches in vaccine development, distribution, and administration. Vaccine types encompass a diverse range of formulations designed to protect children from various infectious diseases, including live attenuated vaccines, inactivated vaccines, subunit vaccines, conjugate vaccines, and recombinant vaccines. Each vaccine type offers unique advantages in terms of efficacy, safety, and immunogenicity, allowing healthcare providers to tailor vaccination strategies based on specific disease targets, age groups, and population characteristics.
Furthermore, segmentation by end use enables the classification of paediatric vaccines based on their intended recipients and administration settings, including routine childhood immunization programs, pediatric clinics, hospitals, and community health centers. Routine childhood immunization programs serve as the primary channel for delivering paediatric vaccines to infants, children, and adolescents, offering essential protection against vaccine-preventable diseases. Pediatric clinics and hospitals play a crucial role in administering vaccines to children during routine well-child visits, sick visits, and specialized care settings, ensuring timely vaccination and continuity of care for paediatric patients.
Geographic segmentation of the paediatric vaccine market allows for a nuanced understanding of regional differences in vaccine demand, healthcare infrastructure, regulatory requirements, and disease epidemiology. Vaccination policies, immunization coverage rates, and vaccine preferences may vary across countries and regions, influencing vaccine uptake and market dynamics. Moreover, geographical segmentation facilitates targeted vaccine distribution strategies, supply chain management, and public health interventions aimed at addressing regional disparities in vaccine access, improving vaccination coverage rates, and reducing the burden of vaccine-preventable diseases among paediatric populations. By leveraging insights from segmented approaches, stakeholders in the global paediatric vaccine market can develop tailored strategies to meet the diverse needs of children worldwide and advance the goal of universal immunization coverage.
Global Paediatric Vaccine Segment Analysis
In this report, the Global Paediatric Vaccine Market has been segmented by Vaccine Type, Technology, Indication, End Use and Geography.
Global Paediatric Vaccine Market, Segmentation by Vaccine Type
The Global Paediatric Vaccine Market has been segmented by Vaccine Type into Monovalent Vaccines and Multivalent Vaccines.
The global paediatric vaccine market has been segmented by vaccine type into monovalent vaccines and multivalent vaccines, reflecting the diversity of vaccine formulations tailored to address specific disease threats and immunization needs among children. Monovalent vaccines target a single pathogen or antigen, providing protection against individual diseases such as measles, mumps, rubella, and varicella. These vaccines are essential components of routine childhood immunization schedules and are administered to children at recommended ages to prevent the onset of infectious diseases that can cause significant morbidity and mortality in paediatric populations.
On the other hand, multivalent vaccines combine multiple antigens or pathogen components into a single formulation, offering protection against two or more diseases with a single vaccination. Multivalent vaccines streamline immunization schedules by reducing the number of injections required and simplifying vaccine administration for children. Examples of multivalent vaccines include combination vaccines like the pentavalent vaccine, which provides protection against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib). By offering comprehensive protection against multiple diseases, multivalent vaccines contribute to higher vaccine coverage rates, improved compliance, and enhanced public health outcomes among paediatric populations.
The segmentation of the paediatric vaccine market into monovalent and multivalent vaccines reflects the diversity of vaccine products available to address the complex immunization needs of children worldwide. While monovalent vaccines target specific diseases, multivalent vaccines offer broader protection against multiple pathogens, providing flexibility and convenience in vaccine delivery. Both types of vaccines play integral roles in childhood immunization programs, contributing to the prevention of infectious diseases and the promotion of health and well-being among paediatric populations globally.
Global Paediatric Vaccine Market, Segmentation by Technology
The Global Paediatric Vaccine Market has been segmented by Technology into Live or Attenuated Vaccine, Inactivated or Killed Vaccine, Toxoid Vaccine, Conjugate Vaccine, Subunit Vaccine, Recombinant Vector Vaccine.
The global paediatric vaccine market has been segmented based on technology into several categories, each offering distinct advantages in preventing diseases among children. Live or attenuated vaccines use weakened forms of the virus or bacteria to stimulate an immune response. These vaccines are highly effective in inducing long-lasting immunity and are commonly used for diseases like measles, mumps, and rubella. However, they are not recommended for immunocompromised individuals, as there is a slight risk of the virus reverting to its pathogenic form.
Inactivated or killed vaccines involve the use of viruses or bacteria that have been killed or inactivated through chemical or physical processes. These vaccines are safe for children with weakened immune systems and are commonly used for diseases such as polio and hepatitis A. While these vaccines typically require booster doses to maintain immunity, they provide a reliable way to protect children from severe infections without the risk associated with live vaccines.
Other types of vaccines in the paediatric market include toxoid vaccines, conjugate vaccines, subunit vaccines, and recombinant vector vaccines. Toxoid vaccines neutralize toxins produced by bacteria, protecting children from diseases like diphtheria and tetanus. Conjugate vaccines link a bacterial antigen to a protein carrier, enhancing the immune response, and are effective in preventing infections like Haemophilus influenzae type b and pneumococcal disease. Subunit vaccines consist of harmless pieces of the pathogen, stimulating the immune system without the whole microorganism, while recombinant vector vaccines use a virus to deliver genetic material from the pathogen to the immune system, offering protection against diseases such as rotavirus. Each of these vaccine types plays a critical role in safeguarding children from a variety of infectious diseases.
Global Paediatric Vaccine Market, Segmentation by Indication
The Global Paediatric Vaccine Market has been segmented by Indication into Pneumococcal Conjugate Vaccine, DTP Vaccine, Influenza, Meningococcal Vaccine, Polio Vaccine, Rotavirus Vaccine, MMR Vaccine, Varicella Virus Vaccine.
The global paediatric vaccine market is divided based on various indications, which include vaccines aimed at protecting children from a range of serious infections. The pneumococcal conjugate vaccine (PCV) plays a vital role in preventing infections caused by Streptococcus pneumoniae, which can lead to conditions like pneumonia, meningitis, and otitis media. Similarly, the DTP vaccine, which provides protection against diphtheria, tetanus, and pertussis, remains a cornerstone of paediatric immunization programs worldwide. These vaccines are crucial in reducing childhood mortality rates associated with these infectious diseases.
Another important segment within the paediatric vaccine market is the influenza vaccine. Seasonal flu vaccines help protect children from influenza virus strains that circulate each year, preventing potentially severe complications. Additionally, vaccines for diseases such as meningococcal infections, polio, and rotavirus are essential for safeguarding children’s health. The meningococcal vaccine, for instance, protects against Neisseria meningitidis, which can cause life-threatening meningitis and bloodstream infections. The polio vaccine, which has played a significant role in the near-eradication of poliovirus globally, continues to be a vital immunization tool in paediatric healthcare.
The MMR vaccine, which combines protection against measles, mumps, and rubella, is another crucial segment in the global market. Measles, in particular, remains a highly contagious disease, and the MMR vaccine has been instrumental in reducing its incidence in children. Additionally, the varicella virus vaccine, which prevents chickenpox, is widely used as part of childhood vaccination schedules. Together, these vaccines ensure a broad spectrum of protection against common but potentially severe childhood diseases, contributing to the overall improvement of child health worldwide.
Global Paediatric Vaccine Market, Segmentation by End Use
The Global Paediatric Vaccine Market has been segmented by End User into Hospital Pharmacies, Retail Pharmacies and Institutional Health Centres.
The global paediatric vaccine market has been segmented by end user into hospital pharmacies, retail pharmacies, and institutional health centers, reflecting the diverse settings where paediatric vaccines are administered and distributed. Hospital pharmacies play a crucial role in providing vaccines to paediatric patients who receive immunization services during hospital visits, outpatient clinics, and emergency departments. With access to a wide range of vaccines and specialized healthcare professionals, hospital pharmacies ensure timely and efficient vaccine delivery, particularly for children requiring vaccinations as part of medical treatment or preventive care.
Retail pharmacies serve as convenient and accessible points of vaccine distribution for paediatric patients and their families, offering vaccines alongside other healthcare products and services. By providing paediatric vaccines in retail settings, such as community pharmacies and drugstores, healthcare providers improve vaccine accessibility and convenience, allowing parents to easily access vaccines for their children during routine shopping trips or healthcare visits. Moreover, retail pharmacies often play a role in vaccine education and promotion, raising awareness about the importance of paediatric immunization and providing guidance on vaccine schedules and recommendations.
Institutional health centers, including schools, daycare centers, and other community-based healthcare facilities, are integral to paediatric vaccine distribution efforts, particularly for routine childhood vaccinations and school entry requirements. These health centers collaborate with healthcare providers, public health agencies, and educational institutions to ensure that children receive recommended vaccines according to national immunization guidelines and school vaccination mandates. By offering vaccination services in institutional settings, healthcare providers reach a broad population of paediatric patients, including those who may face barriers to accessing traditional healthcare facilities. Additionally, institutional health centers often play a role in vaccine surveillance and outbreak response, monitoring vaccine coverage rates and implementing vaccination campaigns to control the spread of vaccine-preventable diseases within communities.
Global Paediatric Vaccine Market, Segmentation by Geography
In this report, the Global Paediatric Vaccine Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Paediatric Vaccine Market Share (%), by Geographical Region, 2024
The global paediatric vaccine market's geographical distribution is diverse, with variations in vaccine coverage rates, immunization policies, and healthcare infrastructure across different regions. North America and Europe hold significant shares of the paediatric vaccine market, driven by well-established immunization programs, robust healthcare systems, and high levels of public awareness regarding the importance of vaccination. These regions benefit from strong regulatory frameworks, government-funded vaccination initiatives, and comprehensive vaccine coverage for paediatric populations, contributing to high vaccination rates and low incidence of vaccine-preventable diseases among children.
In contrast, regions such as Asia-Pacific, Latin America, and Africa exhibit varying degrees of vaccine market penetration and immunization coverage, influenced by factors such as socioeconomic development, healthcare accessibility, and public health policies. While some countries in Asia-Pacific, such as Japan and Australia, boast advanced healthcare systems and high vaccine coverage rates, others face challenges related to vaccine accessibility, affordability, and distribution logistics. Similarly, Latin America and Africa experience disparities in vaccine coverage, with urban areas generally having better access to vaccines than rural or remote regions. Efforts to strengthen healthcare infrastructure, expand immunization programs, and address vaccine access barriers are crucial for improving paediatric vaccine coverage and reducing the burden of vaccine-preventable diseases in these regions.
Moreover, the global paediatric vaccine market is witnessing significant growth opportunities in emerging markets, fueled by increasing investments in healthcare infrastructure, rising awareness of vaccination, and expanding government-led immunization programs. Countries in Asia-Pacific, Latin America, and Africa are investing in strengthening their vaccination systems, enhancing cold chain logistics, and promoting vaccine uptake through public health campaigns and outreach initiatives. Additionally, collaborations between governments, international organizations, and vaccine manufacturers aim to improve vaccine access, affordability, and supply chain efficiency in these regions. As a result, emerging markets are expected to contribute significantly to the growth of the paediatric vaccine market in the coming years, driven by efforts to expand vaccine coverage and protect children from vaccine-preventable diseases.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Paediatric Vaccine Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Expanding Immunization Programs
- Increasing Awareness of Vaccination
-
Advancements in Vaccine Development-Advancements in vaccine development represent a pivotal driver in the global paediatric vaccine market, fueling innovation in the creation of vaccines that are safer, more efficacious, and easier to administer to paediatric populations. Novel vaccine technologies, such as recombinant DNA technology, virus-like particles, and mRNA vaccines, have revolutionized the field by enabling the development of vaccines with improved immunogenicity and reduced risk of adverse reactions. These advancements have facilitated the creation of vaccines against a broader range of infectious diseases, including emerging pathogens, and have accelerated the vaccine development process, leading to faster deployment of vaccines to protect paediatric populations against vaccine-preventable diseases.
Advancements in vaccine development have facilitated the introduction of combination vaccines, which provide protection against multiple diseases with a single injection. Combination vaccines simplify immunization schedules, reduce the number of clinic visits required for vaccination, and improve vaccine coverage rates among paediatric populations. By consolidating multiple antigens into a single vaccine formulation, combination vaccines enhance convenience for healthcare providers and parents while reducing the burden on healthcare systems and resources. Additionally, combination vaccines help address vaccine hesitancy by offering comprehensive protection against multiple diseases with a single administration, thereby increasing vaccine acceptance and compliance among paediatric patients and their caregivers.
Advancements in vaccine development have led to the exploration of new approaches to vaccine design and delivery, such as adjuvants, vector-based vaccines, and novel delivery systems. These innovations aim to enhance vaccine efficacy, stability, and immunogenicity, particularly in vulnerable paediatric populations with immature immune systems. Adjuvants, for example, are substances added to vaccines to enhance the body's immune response, leading to improved vaccine effectiveness and longer-lasting immunity. Similarly, vector-based vaccines use harmless viruses or bacteria as delivery vehicles to transport vaccine antigens into the body, stimulating a robust immune response. By leveraging these advancements, researchers and manufacturers continue to develop next-generation paediatric vaccines that offer enhanced protection against infectious diseases while minimizing the risk of adverse events and maximizing vaccine safety and efficacy.
Restraints:
- Vaccine Hesitancy
- Supply Chain Issues
-
Disparities in Vaccine Access-Disparities in vaccine access represent a significant challenge in the global paediatric vaccine market, contributing to inequities in vaccination coverage and leaving vulnerable populations at higher risk of vaccine-preventable diseases. Factors such as socioeconomic status, geographical location, and healthcare infrastructure influence the availability, affordability, and accessibility of vaccines for paediatric populations. In low- and middle-income countries, where healthcare resources may be limited and public health infrastructure is underdeveloped, access to vaccines can be particularly challenging, leading to lower vaccination rates and higher incidence of vaccine-preventable diseases among children.
Efforts to address disparities in vaccine access require multifaceted strategies that encompass policy interventions, healthcare infrastructure improvements, and community engagement initiatives. Governments and international organizations play a crucial role in implementing policies and programs aimed at improving vaccine access, including vaccine procurement, distribution, and financing mechanisms. By prioritizing immunization as a public health priority and allocating resources to strengthen healthcare systems, countries can expand vaccine coverage and reach underserved paediatric populations effectively.
Community engagement and partnership-building efforts are essential for addressing barriers to vaccine access at the local level. Collaborative initiatives involving healthcare providers, community leaders, non-profit organizations, and grassroots advocates can raise awareness about the importance of vaccination, address vaccine hesitancy, and facilitate vaccine delivery to remote or marginalized communities. Additionally, targeted outreach programs, mobile vaccination clinics, and school-based vaccination campaigns can help overcome logistical challenges and reach children who may otherwise lack access to essential vaccines. By addressing disparities in vaccine access through coordinated and comprehensive strategies, the global paediatric vaccine market can contribute to reducing the burden of vaccine-preventable diseases and improving child health outcomes worldwide.
Opportunities:
- Introduction of Combination Vaccines
- Innovations in Vaccine Platforms
-
Improvements in Vaccine Delivery Systems-Improvements in vaccine delivery systems represent a significant opportunity in the global paediatric vaccine market, offering solutions to overcome challenges associated with traditional injection-based vaccination methods. Novel vaccine delivery technologies aim to enhance vaccine efficacy, safety, and acceptability while improving vaccination coverage rates among paediatric populations. One notable advancement is the development of needle-free delivery systems, such as microneedle patches and jet injectors, which offer painless and convenient alternatives to conventional needle injections. These needle-free devices not only reduce the fear and discomfort associated with needles but also eliminate the risk of needle-stick injuries and enable self-administration in non-clinical settings, facilitating broader vaccine access and uptake.
Innovations in vaccine delivery systems enable the development of thermostable vaccines that do not require refrigeration, addressing challenges related to vaccine storage, transportation, and distribution in resource-limited settings. Thermostable vaccines maintain their potency and efficacy even at elevated temperatures, reducing the dependence on cold chain infrastructure and mitigating the risk of vaccine wastage due to temperature fluctuations during storage and transport. By overcoming logistical barriers and improving vaccine stability, thermostable vaccine formulations enhance vaccine accessibility and enable more effective immunization campaigns, particularly in remote or underserved areas where access to reliable refrigeration may be limited.
Advancements in vaccine delivery systems facilitate the development of novel administration routes, such as mucosal and transdermal vaccination, which offer distinct advantages in stimulating mucosal and systemic immune responses. Mucosal vaccines, administered via oral, nasal, or buccal routes, target mucosal surfaces where many pathogens enter the body, providing an additional layer of protection against respiratory, gastrointestinal, and sexually transmitted infections. Transdermal vaccination, delivered through the skin via patches or microneedles, bypasses the need for needles and offers controlled and sustained release of vaccine antigens, potentially enhancing vaccine immunogenicity and reducing the need for booster doses. By harnessing the potential of alternative administration routes, vaccine developers can broaden the scope of paediatric immunization and address unmet needs in vaccine delivery, paving the way for more effective prevention of infectious diseases among children worldwide.
Competitive Landscape Analysis
Key players in Global Paediatric Vaccine Market include:
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Johnson & Johnson
- Novavax, Inc.
- AstraZeneca plc
- Bharat Biotech
- Sinovac Biotech Ltd.
- Serum Institute of India Pvt. Ltd.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Technology
- Market Snapshot, By Indication
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Paediatric Vaccine Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Expanding Immunization Programs
- Increasing Awareness of Vaccination
- Advancements in Vaccine Development
- Restraints
- Vaccine Hesitancy
- Supply Chain Issues
- Disparities in Vaccine Access
- Opportunities
- Introduction of Combination Vaccines
- Innovations in Vaccine Platforms
- Improvements in Vaccine Delivery Systems
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Paediatric Vaccine Market, By Vaccine Type, 2021 - 2031 (USD Million)
- Monovalent Vaccines
- Multivalent Vaccines
- Paediatric Vaccine Market, By Technology, 2021 - 2031 (USD Million)
- Live or Attenuated Vaccine
- Inactivated or Killed Vaccine
- Toxoid Vaccine
- Conjugate Vaccine
- Subunit Vaccine
- Recombinant Vector Vaccine
- Paediatric Vaccine Market, By Indication, 2021 - 2031 (USD Million)
- Pneumococcal Conjugate Vaccine
- DTP Vaccine
- Influenza
- Meningococcal Vaccine
- Polio Vaccine
- Rotavirus Vaccine
- MMR Vaccine
- Varicella Virus Vaccine
- Paediatric Vaccine Market, By End Use, 2021 - 2031 (USD Million)
- Hospital Pharmacies
- Retail Pharmacies
- Institutional Health Centres
- Paediatric Vaccine Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Paediatric Vaccine Market, By Vaccine Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi
- Johnson & Johnson
- Novavax, Inc.
- AstraZeneca plc
- Bharat Biotech
- Sinovac Biotech Ltd.
- Serum Institute of India Pvt. Ltd.
- Company Profiles
- Analyst Views
- Future Outlook of the Market